ClinicalTrials.gg
CompletedNCT02412306Updated Dec 12, 2022Results posted

Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

A Phase 1/2 interventional study of Blinatumomab in Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia, sponsored by Amgen. Completed at 16 sites in Japan. Open to participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2022-12-12.

Sponsored by Amgen · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
0 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 23 open to participants now, 39 under way, 11 of them phase 3. blinatumomab · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Enrollment
32nd of 61
66 · median 67
Started
2015
with 1 other
Phase 1/2
8 of 61
2 open now
Registered
9th of 61
by date
Lead sponsor
9 of 61
Amgen

Among the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 32nd largest by enrollment, is one of 2 that started in 2015, is one of 8 in phase 1/2, and was the 9th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 473 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

23 of the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

18 more — sign in →

By country, each count listing its studies:

All 23 open studies →

About blinatumomab

blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 370 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (69%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 0 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

This is an open-label, combined 2-part multicenter study to evaluate the efficacy, safety, and tolerability of blinatumomab in adult and pediatric Japanese patients with relapsed/refractory B-precursor ALL.

Read the detailed description

The Phase 1b part will investigate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of blinatumomab to determine the maximum tolerated dose (MTD) in both adult and pediatric Japanese patients with relapsed/refractory B-precursor ALL. The Phase 2 part will assess the safety and efficacy of the recommended dose level of blinatumomab identified in the Phase 1b portion of the study in the adult study population.

In June 2017 protocol amendment 4 extended the study to include an expansion cohort of approximately 65 participants to investigate the safety of blinatumomab in participants who did not participate in Phase 1b or Phase 2 of the study. Adult and pediatric patients in the expansion cohort may receive up to 5 cycles of investigational blinatomumab and may receive commercial blinatomumab after a minimum of 2 cycles of the investigational drug.

03

Conditions studied

  • Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia

Keywords

  • Amgen
04

Who can participate

Ages eligible
0 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Adult Subjects Key Inclusion Criteria:

  • Age ≥ 18 years old at enrollment
  • Subjects with Philadelphia-negative B-precursor ALL, with any of the following:

    • after therapy with first remission duration ≤ 12 months; or
    • Relapsed or refractory after first salvage therapy; or
    • Relapsed or refractory within 12 months of hematopoietic stem cell transplant (alloHSCT)
  • (ECOG) Performance Status of 0, 1, or 2.
  • Greater than 5% blasts in bone marrow

Pediatric Subjects Key Inclusion Criteria:

  • Age \< 18 years old at enrollment
  • Relapsed/refractory disease, defined as one of the following:

    • second or later bone marrow relapse;
    • any marrow relapse after alloHSCT; or
    • Refractory to other treatments:

      • For subjects in first relapse: failure to achieve a complete response (CR) following a full standard reinduction chemotherapy regimen
      • For subjects who have not achieved a first remission: failure to achieve remission following a full standard induction regimen
  • Greater than 5% blasts in bone marrow
  • performance status ≥ 50% for subjects ≥ 16 years
  • Lansky performance status ≥ 50% for subjects \< 16 years

Key Exclusion Criteria

  • Subjects with Burkitt´s Leukemia according to World Health Organization (WHO) classification
  • History or presence of central nervous system (CNS) pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis; with the exception of well-controlled CNS leukemia
  • Active ALL in the CNS or testes
  • Current disease or history of autoimmune disease with potential CNS involvement
  • Autologous HSCT within 6 weeks prior to start of blinatumomab treatment
  • AlloHSCT within 12 weeks prior to start of blinatumomab treatment
  • Any active acute (GvHD) grade 2-4 according to Glucksberg criteria or active chronic GvHD requiring systemic treatment
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Blinatumomab 9-28 µg/day Phase 1b Adult Population

    Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.

    Drug: Blinatumomab

  • Experimental
    Blinatumomab 5-15 µg/m^2/day Phase 1b Pediatric Population

    Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. For pediatric participants the initial dose was 5 µg/m²/day for the first week of cycle 1, escalated to 15 µg/m²/day starting from week 2 and all cycles thereafter.

    Drug: Blinatumomab

  • Experimental
    Blinatumomab 9-28 µg/day Phase 2 Adult Population

    Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.

    Drug: Blinatumomab

  • Experimental
    Blinatumomab 9-28 µg/day Adult Expansion Population

    Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.

    Drug: Blinatumomab

  • Experimental
    Blinatumomab 5-15 µg/m^2/day Pediatric Expansion Population

    Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. For pediatric participants the initial dose was 5 µg/m²/day for the first week of cycle 1, escalated to 15 µg/m²/day starting from week 2 and all cycles thereafter.

    Drug: Blinatumomab

Interventions

  • Continuous intravenous infusion over four weeks per treatment cycle

    Also known as: Blincyto®

06

What researchers measure

Primary outcomes

  1. Phase 1b: Number of Participants With Dose-limiting Toxicities

    Dose-limiting toxicities (DLTs) were defined as any Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 grade ≥ 3 adverse event related to blinatumomab, excluding specific CTCAE grade ≥ 3 adverse events considered consistent with the current known safety profile of blinatumomab, CTCAE grade ≥ 3 fever or infection, and laboratory parameters of CTCAE grade ≥ 3 not considered clinically relevant and/or responding to routine medical management.

    Time frame: Days 1 to 14

  2. Phase 2: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment

    Hematological assessments were performed from bone marrow biopsy samples. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Hematological remissions were defined by the following criteria: * Complete Remission (CR) is defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts: platelets \> 100,000/µl and absolute neutrophil count (ANC) \> 1,000/µl. * Complete Remission With Partial Hematological Recovery (CRh\*) is defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts: platelets \> 50,000/µl and ANC \> 500/µl.

    Time frame: Within the first 2 cycles of treatment, 12 weeks

  3. Expansion Cohort: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related TEAEs

    TEAEs are defined as those that start between the start of the first infusion of blinatumomab and 30 days after the end of the last infusion during the treatment period. The severity of adverse events was assessed by the investigator according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 as follows: Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death. The investigator used medical judgment to determine if there was a causal relationship (ie, related, unrelated) between an adverse event and blinatumomab.

    Time frame: From the start of the first infusion to 30 days after the end of the last infusion; median (min, max) treatment duration was 55.6 (25, 140) and 28.0 (8, 56) days in the adult and pediatric expansion cohorts, respectively.

Secondary outcomes

  1. Phase 1b Adults: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment

    Hematological assessments were performed from bone marrow biopsy samples. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Hematological remissions were defined by the following criteria: * Complete Remission (CR) is defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts: platelets \> 100,000/µl and absolute neutrophil count (ANC) \> 1,000/µl. * Complete Remission With Partial Hematological Recovery (CRh\*) is defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts: platelets \> 50,000/µl and ANC \> 500/µl

    Time frame: Within the first 2 cycles of treatment, 12 weeks

  2. Phase 1b Pediatric: Percentage of Participants With M1 Remission Within 2 Cycles of Treatment

    M1 remission for pediatric participants was defined as ≤ 5% blasts (M1 bone marrow) in the bone marrow and no evidence of disease.

    Time frame: The first 2 cycles of treatment, 12 weeks

  3. Phase 1b and Phase 2: Duration of Response

    Duration of response was calculated from the date of bone marrow aspiration when response (CR/CRh\*) was detected for the first time during the first 2 cycles of treatment until the earlier of the following events: * the date of bone marrow aspiration at which hematological relapse or progressive disease (PD) was first detected, * the date of diagnosis on which the hematological or extra medullary relapse was documented, * the date of death if patient died due to PD * the date of end of induction phase if primary reason for treatment termination was hematological or extramedullary relapse. For a responder who did not report an event and was alive during the study, the end date of duration (censoring) was based on the date of the last available bone marrow aspiration prior to the data cutoff date for the analysis. Participants with response who did not report an event and who died due to reasons other than PD, were censored on the date of death, with death treated as a competing risk.

    Time frame: Median (minimum [min], maximum [max]) follow-up time was 6.3 (2.4, 13.6) months for Phase 1b and 26.7 (3.0, 28.5) months for Phase 2.

  4. Phase 1b and Phase 2: Relapse-free Survival

    Relapse-free survival (RFS) was defined for participants who achieved a response (CR/CRh\*) during the first 2 cycles of treatment. RFS was calculated from the date of bone marrow aspiration when response was detected for the first time to the date of bone marrow aspiration at which hematological relapse was first detected or the date of diagnosis on which the hematological or extra medullary relapse was documented or the date of death due to any cause, whichever was earlier. Participants who did not experience hematological relapse and did not die were censored on the date of the last available bone marrow aspiration prior to the data cutoff date for the analysis.

    Time frame: Median (min, max) follow-up time was 6.3 (2.4, 13.6) months for Phase 1b and 26.7 (3.0, 28.5) months for Phase 2.

  5. Phase 1b and Phase 2: Overall Survival

    Overall survival (OS) was calculated from the start date of blinatumomab infusion in the first treatment cycle. All deaths were counted as events on the date of death. Participants still alive were censored on the last documented visit date or the date of the last phone contact when the participant was last known to have been alive. For participants who withdrew their informed consent, only information until the date of withdrawal was used in the analysis.

    Time frame: Median (min, max) follow-up time was 6.3 (2.4, 13.6) months for Phase 1b and 26.7 (3.0, 28.5) months for Phase 2.

  6. Phase 2: Best Overall Response Within 2 Cycles of Treatment

    Best response was defined as one of the following: CR: ≤ 5% blasts in the bone marrow (BM); No evidence of disease; Full recovery of peripheral blood counts: Platelets \> 100,000/µl, and absolute neutrophil count (ANC) \> 1,000/µl CRh\*: ≤ 5% blasts in BM; No evidence of disease; Partial recovery of peripheral blood counts: Platelets \> 50,000/µl, and ANC \> 500/µl CRi: CR with incomplete count recovery without CRh\* Blast free hypoplastic or aplastic BM: ≤ 5 % blasts in BM; No evidence of disease; Insufficient recovery of peripheral blood counts: platelets ≤ 50,000/µl and/or ANC ≤ 500/µl Partial Remission: BM blasts \> 5 to \< 25% with at least a 50% reduction from baseline Hematological Relapse: \> 5% blasts in BM or blasts in peripheral blood after documented CR/CRh\* during the study PD: An increase from baseline of ≥ 25% of BM blasts or an absolute increase of ≥ 5,000 cells/µL in the number of circulating leukemia cells.

    Time frame: Within the first 2 cycles of treatment, 12 weeks

  7. Phase 2: Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) During Blinatumomab Induced Remission

    Participants who were eligible for allogeneic HSCT were those who achieved remission (complete response or complete response with partial recovery of peripheral blood counts) after 2 cycles of blinatumomab treatment, and no further anti-leukemic medication was given before HSCT.

    Time frame: Median (min, max) follow-up time was 26.7 (3.0, 28.5) months.

  8. Phase 2: 100-Day Mortality After Allogeneic HSCT

    The analysis of 100-day mortality after allogeneic HSCT was assessed for all participants who received an allogeneic HSCT while in any CR following treatment with blinatumomab. 100-day mortality after allogeneic HSCT was calculated relative to the date of allogeneic HSCT. Participants still alive alive were censored on the last documented visit date or the date of the last phone contact when the patient was last known to have been alive. The 100-day mortality rate after allogeneic HSCT was defined as the percentage of participants having died up to 100 days after allogeneic HSCT estimated using the estimated time to death in percent calculated by Kaplan-Meier methods.

    Time frame: 100 days, from the date of allogeneic HSCT; median (min, max) follow-up time was 26.7 (3.0, 28.5)

  9. Phase 1b and Phase 2: Number of Participants With TEAEs

    TEAEs are defined as those that start between the start of the first infusion of blinatumomab and 30 days after the end of the last infusion during the treatment period. The severity of adverse events was assessed by the investigator according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 as follows: Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death. The investigator used medical judgment to determine if there was a causal relationship (ie, related, unrelated) between an adverse event and blinatumomab.

    Time frame: From the start of the first infusion to 30 days after the end of the last infusion; median (min, max) treatment duration was 108 (56, 140), 56.0 (5, 84), and 56.0 (11, 115) days in adult phase 1b, adult phase 2 and pediatric phase 1b cohort respectively.

  10. Phase 1b and Phase 2: Serum Blinatumomab Concentration at Steady State

    The steady-state concentration (Css) of serum blinatumomab was summarized as the average of the observed concentrations collected after 5 half-lives or after 24 hours from the start of continuous IV infusion. Cycle 1, day 2 values represent steady-state concentration after CIV with the initial dose of blinatumomab (9 µg/day for adults and 5 µg/m²/day for pediatric patients). All other time points were measured after the dose step to 28 µg/day (adults) / 15 µg/m²/day (pediatric participants).

    Time frame: After 24 hours from the start of infusion: Cycle 1 (before dose step) day 2; Cycle 1 (after dose step) days 15 and 29; Cycle 2 onwards day 8 (pediatric and adult), days 15 and 29 (adult).

  11. Phase 1b and Phase 2: Systemic Clearance of Blinatumomab

    Systemic clearance (CL) was calculated as CL = R0/Css, where R0 is the infusion rate (µg/hour or µg/m²/hour).

    Time frame: After 24 hours from the start of infusion: Cycle 1 (before dose step) day 2; Cycle 1 (after dose step) days 15 and 29; Cycle 2 onwards day 8 (pediatric and adult), days 15 and 29 (adult).

  12. Phase 1b and Phase 2: Terminal Half-life of Blinatumomab

    Time frame: Cycle 1 day 1 predose, 2, 6 (adults), 10, 24 hours; day 8 (prior to dose step) 0 hour (adults); day 15 any time during infusion; day 29 prior to end of infusion, 1 (adults), 2, 4 (adults), 6 hours after end of infusion

  13. Phase 1b and Phase 2: Volume of Distribution of Blinatumomab

    Time frame: Cycle 1 day 1 predose, 2, 6 (adults), 10, 24 hours; day 8 (prior to dose step) 0 hour (adults); day 15 any time during infusion; day 29 prior to end of infusion, 1 (adults), 2, 4 (adults), 6 hours after end of infusion

  14. Phase 1b and Phase 2: Number of Participants Who Developed Anti-Blinatumomab Antibodies

    Antibodies to blinatumomab were detected using an electrochemiluminescence (ECL)-based assay.

    Time frame: Day 1 before first dose; cycles 1 and 2 day 29, 6 hours after end of infusion; 30 days after last dose.

  15. Phase 1b and Phase 2: Interleukin-2 Concentration

    The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) was 125 pg/mL and the limit of detection (LOD) was 20 pg/mL. For calculations of mean cytokine concentrations at every time point across all participants, samples with concentrations below LLOQ were included in the calculation as ½ LLOQ (= 62.5 pg/mL); samples with values below LOD were included as ½ LOD (= 10 pg/mL).

    Time frame: Adults: cycle 1, day 1: 2, 6, 10, 24 hrs after infusion start; day 8: 2, 6, 10 hrs after dose step. Cycles 2-5, day 1: 6 hrs after infusion start. Pediatric: cycle 1, day 1: 6, 10, 24 hrs after infusion start; Cycles 2-5, day 1: 6 hrs after infusion start

  16. Phase 1b and Phase 2: Interleukin-6 Concentration

    The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) was 125 pg/mL and the limit of detection (LOD) was 20 pg/mL. For calculations of mean cytokine concentrations at every time point across all participants, samples with concentrations below LLOQ were included in the calculation as ½ LLOQ (= 62.5 pg/mL); samples with values below LOD were included as ½ LOD (= 10 pg/mL).

    Time frame: Adults: cycle 1, day 1: 2, 6, 10, 24 hrs after infusion start; day 8: 2, 6, 10 hrs after dose step. Cycles 2-5, day 1: 6 hrs after infusion start. Pediatric: cycle 1, day 1: 6, 10, 24 hrs after infusion start; Cycles 2-5, day 1: 6 hrs after infusion start

  17. Phase 1b and Phase 2: Interleukin-10 Concentration

    The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) was 125 pg/mL and the limit of detection (LOD) was 20 pg/mL. For calculations of mean cytokine concentrations at every time point across all participants, samples with concentrations below LLOQ were included in the calculation as ½ LLOQ (= 62.5 pg/mL); samples with values below LOD were included as ½ LOD (= 10 pg/mL).

    Time frame: Adults: cycle 1, day 1: 2, 6, 10, 24 hrs after infusion start; day 8: 2, 6, 10 hrs after dose step. Cycles 2-5, day 1: 6 hrs after infusion start. Pediatric: cycle 1, day 1: 6, 10, 24 hrs after infusion start; Cycles 2-5, day 1: 6 hrs after infusion start

  18. Phase 1b and Phase 2: Tumor Necrosis Factor-Alpha (TNFα) Concentration

    The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) was 125 pg/mL and the limit of detection (LOD) was 20 pg/mL. For calculations of mean cytokine concentrations at every time point across all participants, samples with concentrations below LLOQ were included in the calculation as ½ LLOQ (= 62.5 pg/mL); samples with values below LOD were included as ½ LOD (= 10 pg/mL).

    Time frame: Adults: cycle 1, day 1: 2, 6, 10, 24 hrs after infusion start; day 8: 2, 6, 10 hrs after dose step. Cycles 2-5, day 1: 6 hrs after infusion start. Pediatric: cycle 1, day 1: 6, 10, 24 hrs after infusion start; Cycles 2-5, day 1: 6 hrs after infusion start

  19. Phase 1b and Phase 2: Interferon Gamma (IFN-γ) Concentration

    The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) was 125 pg/mL and the limit of detection (LOD) was 20 pg/mL. For calculations of mean cytokine concentrations at every time point across all participants, samples with concentrations below LLOQ were included in the calculation as ½ LLOQ (= 62.5 pg/mL); samples with values below LOD were included as ½ LOD (= 10 pg/mL).

    Time frame: Adults: cycle 1, day 1: 2, 6, 10, 24 hrs after infusion start; day 8: 2, 6, 10 hrs after dose step. Cycles 2-5, day 1: 6 hrs after infusion start. Pediatric: cycle 1, day 1: 6, 10, 24 hrs after infusion start; Cycles 2-5, day 1: 6 hrs after infusion start

  20. Expansion Cohort Adult: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment

    Hematological assessments were performed from bone marrow biopsy samples. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Hematological remissions were defined by the following criteria: * Complete Remission (CR) is defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts: platelets \> 100,000/µl and absolute neutrophil count (ANC) \> 1,000/µl. * Complete Remission With Partial Hematological Recovery (CRh\*) is defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts: platelets \> 50,000/µl and ANC \> 500/µl.

    Time frame: Within the first 2 cycles of treatment, 12 weeks

  21. Expansion Cohort Pediatric: Percentage of Participants With M1 Remission Within 2 Cycles of Treatment

    M1 remission for pediatric participants was defined as ≤ 5% blasts (M1 bone marrow) in the bone marrow and no evidence of disease.

    Time frame: Within the first 2 cycles of treatment, 12 weeks

07

Results

Posted Jan 10, 2020

Participant flow

Study was conducted at 16 centers in Japan. Cohort enrollment periods were: adult phase 1b, from 04 Jun 2015 to 13 Jan 2016; pediatric phase 1b, from 17 Feb 2016 to 20 Jun 2016; adult phase 2, from 11 Apr 2016 to 12 Jun 2017; adult expansion cohort, from 04 Dec 2017 to 13 Nov 2018; pediatric expansion cohort, from 05 Nov 2017 to 05 Sep 2018.

Participant flow — Overall Study
MilestonePhase 1b: Blinatumomab 9/28 μg/Day (Adults)Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric)Phase 2: Blinatumomab 9/28 μg/Day (Adults)Expansion Cohort: Blinatumomab 9/28 μg/Day (Adults)Expansion Cohort: Blinatumomab 5/15 µg/m²/Day (Pediatric)
Started59211417
Completed0151415
Not completed581602
Withdrew: Lost to follow-up01000
Withdrew: Withdrawal by subject00100
Withdrew: Death571502

Outcome measures

PrimaryPhase 1b: Number of Participants With Dose-limiting Toxicities

Dose-limiting toxicities (DLTs) were defined as any Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 grade ≥ 3 adverse event related to blinatumomab, excluding specific CTCAE grade ≥ 3 adverse events considered consistent with the current known safety profile of blinatumomab, CTCAE grade ≥ 3 fever or infection, and laboratory parameters of CTCAE grade ≥ 3 not considered clinically relevant and/or responding to routine medical management.

Time frame:
Days 1 to 14
Reported as:
Count of participants · Participants
Phase 1b: Number of Participants With Dose-limiting Toxicities
ParticipantsPhase 1b: Blinatumomab 9/28 μg/Day (Adults)Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric)
Phase 1b: Number of Participants With Dose-limiting Toxicities00
PrimaryPhase 2: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment

Hematological assessments were performed from bone marrow biopsy samples. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Hematological remissions were defined by the following criteria: * Complete Remission (CR) is defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts: platelets \> 100,000/µl and absolute neutrophil count (ANC) \> 1,000/µl. * Complete Remission With Partial Hematological Recovery (CRh\*) is defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts: platelets \> 50,000/µl and ANC \> 500/µl.

Time frame:
Within the first 2 cycles of treatment, 12 weeks
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment
percentage of participantsPhase 2: Blinatumomab 9/28 μg/Day (Adults)
Phase 2: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment38.1 (18.1 to 61.6)
SecondaryPhase 1b Adults: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment

Hematological assessments were performed from bone marrow biopsy samples. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Hematological remissions were defined by the following criteria: * Complete Remission (CR) is defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts: platelets \> 100,000/µl and absolute neutrophil count (ANC) \> 1,000/µl. * Complete Remission With Partial Hematological Recovery (CRh\*) is defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts: platelets \> 50,000/µl and ANC \> 500/µl

Time frame:
Within the first 2 cycles of treatment, 12 weeks
Reported as:
Number · percentage of participants
Phase 1b Adults: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment
percentage of participantsPhase 1b: Blinatumomab 9/28 μg/Day (Adults)
Phase 1b Adults: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment80.0 (28.4 to 99.5)
SecondaryPhase 1b Pediatric: Percentage of Participants With M1 Remission Within 2 Cycles of Treatment

M1 remission for pediatric participants was defined as ≤ 5% blasts (M1 bone marrow) in the bone marrow and no evidence of disease.

Time frame:
The first 2 cycles of treatment, 12 weeks
Reported as:
Number · percentage of participants
Phase 1b Pediatric: Percentage of Participants With M1 Remission Within 2 Cycles of Treatment
percentage of participantsPhase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric)
Phase 1b Pediatric: Percentage of Participants With M1 Remission Within 2 Cycles of Treatment55.6 (21.2 to 86.3)
SecondaryPhase 1b and Phase 2: Duration of Response

Duration of response was calculated from the date of bone marrow aspiration when response (CR/CRh\*) was detected for the first time during the first 2 cycles of treatment until the earlier of the following events: * the date of bone marrow aspiration at which hematological relapse or progressive disease (PD) was first detected, * the date of diagnosis on which the hematological or extra medullary relapse was documented, * the date of death if patient died due to PD * the date of end of induction phase if primary reason for treatment termination was hematological or extramedullary relapse. For a responder who did not report an event and was alive during the study, the end date of duration (censoring) was based on the date of the last available bone marrow aspiration prior to the data cutoff date for the analysis. Participants with response who did not report an event and who died due to reasons other than PD, were censored on the date of death, with death treated as a competing risk.

Time frame:
Median (minimum [min], maximum [max]) follow-up time was 6.3 (2.4, 13.6) months for Phase 1b and 26.7 (3.0, 28.5) months for Phase 2.
Reported as:
Median · months
Phase 1b and Phase 2: Duration of Response
monthsPhase 1b: Blinatumomab 9/28 μg/Day (Adults)Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric)Phase 2: Blinatumomab 9/28 μg/Day (Adults)
Phase 1b and Phase 2: Duration of Response13.0 (4.2 to 19.7)2.3 (1.1 to 6.8)13.1 (3.5 to 20.7)
SecondaryPhase 1b and Phase 2: Relapse-free Survival

Relapse-free survival (RFS) was defined for participants who achieved a response (CR/CRh\*) during the first 2 cycles of treatment. RFS was calculated from the date of bone marrow aspiration when response was detected for the first time to the date of bone marrow aspiration at which hematological relapse was first detected or the date of diagnosis on which the hematological or extra medullary relapse was documented or the date of death due to any cause, whichever was earlier. Participants who did not experience hematological relapse and did not die were censored on the date of the last available bone marrow aspiration prior to the data cutoff date for the analysis.

Time frame:
Median (min, max) follow-up time was 6.3 (2.4, 13.6) months for Phase 1b and 26.7 (3.0, 28.5) months for Phase 2.
Reported as:
Median · months
Phase 1b and Phase 2: Relapse-free Survival
monthsPhase 1b: Blinatumomab 9/28 μg/Day (Adults)Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric)Phase 2: Blinatumomab 9/28 μg/Day (Adults)
Phase 1b and Phase 2: Relapse-free Survival11.4 (4.2 to 19.7)2.3 (1.1 to 6.8)13.1 (3.5 to 20.7)
SecondaryPhase 1b and Phase 2: Overall Survival

Overall survival (OS) was calculated from the start date of blinatumomab infusion in the first treatment cycle. All deaths were counted as events on the date of death. Participants still alive were censored on the last documented visit date or the date of the last phone contact when the participant was last known to have been alive. For participants who withdrew their informed consent, only information until the date of withdrawal was used in the analysis.

Time frame:
Median (min, max) follow-up time was 6.3 (2.4, 13.6) months for Phase 1b and 26.7 (3.0, 28.5) months for Phase 2.
Reported as:
Median · months
Phase 1b and Phase 2: Overall Survival
monthsPhase 1b: Blinatumomab 9/28 μg/Day (Adults)Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric)Phase 2: Blinatumomab 9/28 μg/Day (Adults)
Phase 1b and Phase 2: Overall Survival11.0 (9.3 to 20.7)10.6 (0.9 to NA)14.8 (2.7 to 21.6)
SecondaryPhase 2: Best Overall Response Within 2 Cycles of Treatment

Best response was defined as one of the following: CR: ≤ 5% blasts in the bone marrow (BM); No evidence of disease; Full recovery of peripheral blood counts: Platelets \> 100,000/µl, and absolute neutrophil count (ANC) \> 1,000/µl CRh\*: ≤ 5% blasts in BM; No evidence of disease; Partial recovery of peripheral blood counts: Platelets \> 50,000/µl, and ANC \> 500/µl CRi: CR with incomplete count recovery without CRh\* Blast free hypoplastic or aplastic BM: ≤ 5 % blasts in BM; No evidence of disease; Insufficient recovery of peripheral blood counts: platelets ≤ 50,000/µl and/or ANC ≤ 500/µl Partial Remission: BM blasts \> 5 to \< 25% with at least a 50% reduction from baseline Hematological Relapse: \> 5% blasts in BM or blasts in peripheral blood after documented CR/CRh\* during the study PD: An increase from baseline of ≥ 25% of BM blasts or an absolute increase of ≥ 5,000 cells/µL in the number of circulating leukemia cells.

Time frame:
Within the first 2 cycles of treatment, 12 weeks
Reported as:
Count of participants · Participants
Phase 2: Best Overall Response Within 2 Cycles of Treatment
ParticipantsPhase 2: Blinatumomab 9/28 μg/Day (Adults)
CR5
CRh*3
CRi0
Blast-free hypoplastic or aplastic bone marrow6
Partial remission0
Hematological relapse0
PD2
No response (none of the above)5
SecondaryPhase 2: Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) During Blinatumomab Induced Remission

Participants who were eligible for allogeneic HSCT were those who achieved remission (complete response or complete response with partial recovery of peripheral blood counts) after 2 cycles of blinatumomab treatment, and no further anti-leukemic medication was given before HSCT.

Time frame:
Median (min, max) follow-up time was 26.7 (3.0, 28.5) months.
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) During Blinatumomab Induced Remission
percentage of participantsPhase 2: Blinatumomab 9/28 μg/Day (Adults)
Phase 2: Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) During Blinatumomab Induced Remission81.0
SecondaryPhase 2: 100-Day Mortality After Allogeneic HSCT

The analysis of 100-day mortality after allogeneic HSCT was assessed for all participants who received an allogeneic HSCT while in any CR following treatment with blinatumomab. 100-day mortality after allogeneic HSCT was calculated relative to the date of allogeneic HSCT. Participants still alive alive were censored on the last documented visit date or the date of the last phone contact when the patient was last known to have been alive. The 100-day mortality rate after allogeneic HSCT was defined as the percentage of participants having died up to 100 days after allogeneic HSCT estimated using the estimated time to death in percent calculated by Kaplan-Meier methods.

Time frame:
100 days, from the date of allogeneic HSCT; median (min, max) follow-up time was 26.7 (3.0, 28.5)
Reported as:
Number · percentage of participants
Phase 2: 100-Day Mortality After Allogeneic HSCT
percentage of participantsPhase 2: Blinatumomab 9/28 μg/Day (Adults)
Phase 2: 100-Day Mortality After Allogeneic HSCT11.8
SecondaryPhase 1b and Phase 2: Number of Participants With TEAEs

TEAEs are defined as those that start between the start of the first infusion of blinatumomab and 30 days after the end of the last infusion during the treatment period. The severity of adverse events was assessed by the investigator according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 as follows: Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death. The investigator used medical judgment to determine if there was a causal relationship (ie, related, unrelated) between an adverse event and blinatumomab.

Time frame:
From the start of the first infusion to 30 days after the end of the last infusion; median (min, max) treatment duration was 108 (56, 140), 56.0 (5, 84), and 56.0 (11, 115) days in adult phase 1b, adult phase 2 and pediatric phase 1b cohort respectively.
Reported as:
Count of participants · Participants
Phase 1b and Phase 2: Number of Participants With TEAEs
ParticipantsPhase 1b: Blinatumomab 9/28 μg/Day (Adults)Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric)Phase 2: Blinatumomab 9/28 μg/Day (Adults)
All TEAEs5921
TEAEs ≥ Grade 34921
TEAEs ≥ Grade 42714
Serious TEAEs (STEAEs)017
TEAEs Leading to Blinatumomab Interruption163
STEAEs Leading to Blinatumomab Interruption000
TEAEs Leading to Blinatumomab Discontinuation011
STEAEs Leading to Blinatumomab Discontinuation001
Fatal TEAEs011
All Treatment-Related (TR) TEAEs5821
TR TEAEs ≥ Grade 32818
TR TEAEs ≥ Grade 41511
TR STEAEs004
TR TEAEs Leading to Blinatumomab Interruption161
TR STEAEs Leading to Blinatumomab Interruption000
TR TEAEs Leading to Blinatumomab Discontinuation011
TR STEAEs Leading to Blinatumomab Discontinuation001
TR Fatal TEAEs000
SecondaryPhase 1b and Phase 2: Serum Blinatumomab Concentration at Steady State

The steady-state concentration (Css) of serum blinatumomab was summarized as the average of the observed concentrations collected after 5 half-lives or after 24 hours from the start of continuous IV infusion. Cycle 1, day 2 values represent steady-state concentration after CIV with the initial dose of blinatumomab (9 µg/day for adults and 5 µg/m²/day for pediatric patients). All other time points were measured after the dose step to 28 µg/day (adults) / 15 µg/m²/day (pediatric participants).

Time frame:
After 24 hours from the start of infusion: Cycle 1 (before dose step) day 2; Cycle 1 (after dose step) days 15 and 29; Cycle 2 onwards day 8 (pediatric and adult), days 15 and 29 (adult).
Reported as:
Mean · pg/mL
Phase 1b and Phase 2: Serum Blinatumomab Concentration at Steady State
pg/mLBlinatumomab 9/28 μg/Day (Phase 1b and Phase 2 Adults)Blinatumomab 5/15 µg/m²/Day (Phase 1b and Phase 2 Pediatric)Blinatumomab 9/28 μg/Day (Phase 1b Only Adults)Blinatumomab 5/15 µg/m²/Day (Phase 1b Only Pediatric)
Cycle 1 before dose step191 ± 90.8113 ± 65.0135 ± 41.7107 ± 42.7
Cycle 1 after dose step948 ± 488361 ± 137907 ± 403361 ± 137
Cycle 21150 ± 575427 ± 66.01040 ± 493427 ± 66.0
Cycle 3+1420 ± 685780 ± NA1280 ± 396—
SecondaryPhase 1b and Phase 2: Systemic Clearance of Blinatumomab

Systemic clearance (CL) was calculated as CL = R0/Css, where R0 is the infusion rate (µg/hour or µg/m²/hour).

Time frame:
After 24 hours from the start of infusion: Cycle 1 (before dose step) day 2; Cycle 1 (after dose step) days 15 and 29; Cycle 2 onwards day 8 (pediatric and adult), days 15 and 29 (adult).
Reported as:
Mean · liters/hour
Phase 1b and Phase 2: Systemic Clearance of Blinatumomab
liters/hourBlinatumomab 9/28 μg/Day (Phase 1b and Phase 2 Adults)Blinatumomab 5/15 µg/m²/Day (Phase 1b and Phase 2 Pediatric)Blinatumomab 9/28 μg/Day (Phase 1b Only Adults)Blinatumomab 5/15 µg/m²/Day (Phase 1b Only Pediatric)
Phase 1b and Phase 2: Systemic Clearance of Blinatumomab1.59 ± 0.8121.88 ± 0.7891.59 ± 0.9981.83 ± 0.801
SecondaryPhase 1b and Phase 2: Terminal Half-life of Blinatumomab
Time frame:
Cycle 1 day 1 predose, 2, 6 (adults), 10, 24 hours; day 8 (prior to dose step) 0 hour (adults); day 15 any time during infusion; day 29 prior to end of infusion, 1 (adults), 2, 4 (adults), 6 hours after end of infusion
Reported as:
Mean · hours
Phase 1b and Phase 2: Terminal Half-life of Blinatumomab
hoursBlinatumomab 9/28 μg/Day (Phase 1b and Phase 2 Adults)Blinatumomab 5/15 µg/m²/Day (Phase 1b and Phase 2 Pediatric)Blinatumomab 9/28 μg/Day (Phase 1b Only Adults)Blinatumomab 5/15 µg/m²/Day (Phase 1b Only Pediatric)
Phase 1b and Phase 2: Terminal Half-life of Blinatumomab2.38 ± 1.361.92 ± 1.122.60 ± 2.032.62 ± 1.67
SecondaryPhase 1b and Phase 2: Volume of Distribution of Blinatumomab
Time frame:
Cycle 1 day 1 predose, 2, 6 (adults), 10, 24 hours; day 8 (prior to dose step) 0 hour (adults); day 15 any time during infusion; day 29 prior to end of infusion, 1 (adults), 2, 4 (adults), 6 hours after end of infusion
Reported as:
Mean · liters
Phase 1b and Phase 2: Volume of Distribution of Blinatumomab
litersBlinatumomab 9/28 μg/Day (Phase 1b and Phase 2 Adults)Blinatumomab 5/15 µg/m²/Day (Phase 1b and Phase 2 Pediatric)Blinatumomab 9/28 μg/Day (Phase 1b Only Adults)Blinatumomab 5/15 µg/m²/Day (Phase 1b Only Pediatric)
Phase 1b and Phase 2: Volume of Distribution of Blinatumomab6.02 ± 6.095.05 ± 3.358.22 ± 11.76.38 ± 3.95
SecondaryPhase 1b and Phase 2: Number of Participants Who Developed Anti-Blinatumomab Antibodies

Antibodies to blinatumomab were detected using an electrochemiluminescence (ECL)-based assay.

Time frame:
Day 1 before first dose; cycles 1 and 2 day 29, 6 hours after end of infusion; 30 days after last dose.
Reported as:
Count of participants · Participants
Phase 1b and Phase 2: Number of Participants Who Developed Anti-Blinatumomab Antibodies
ParticipantsPhase 1b: Blinatumomab 9/28 μg/Day (Adults)Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric)Phase 2: Blinatumomab 9/28 μg/Day (Adults)
Phase 1b and Phase 2: Number of Participants Who Developed Anti-Blinatumomab Antibodies000
SecondaryPhase 1b and Phase 2: Interleukin-2 Concentration

The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) was 125 pg/mL and the limit of detection (LOD) was 20 pg/mL. For calculations of mean cytokine concentrations at every time point across all participants, samples with concentrations below LLOQ were included in the calculation as ½ LLOQ (= 62.5 pg/mL); samples with values below LOD were included as ½ LOD (= 10 pg/mL).

Time frame:
Adults: cycle 1, day 1: 2, 6, 10, 24 hrs after infusion start; day 8: 2, 6, 10 hrs after dose step. Cycles 2-5, day 1: 6 hrs after infusion start. Pediatric: cycle 1, day 1: 6, 10, 24 hrs after infusion start; Cycles 2-5, day 1: 6 hrs after infusion start
Reported as:
Mean · pg/mL
Phase 1b and Phase 2: Interleukin-2 Concentration
pg/mLPhase 1b and Phase 2: Blinatumomab 9/28 μg/Day (Adults)Phase 1b and Phase 2: Blinatumomab 5/15 µg/m²/Day (Pediatric)
Cycle 1, day 1, 2 hours after start of infusion16.1 ± 17.1—
Cycle 1, day 1, 6 hours after start of infusion30.2 ± 72.810.0 ± 0.0
Cycle 1, day 1, 10 hours after start of infusion32.6 ± 85.010.0 ± 0.0
Cycle 1, day 1, 24 hours after start of infusion17.2 ± 36.729.8 ± 55.9
Cycle 1, day 8, 2 hours after start of infusion10.0 ± 0.0—
Cycle 1, day 8, 6 hours after start of infusion10.0 ± 0.0—
Cycle 1, day 8, 10 hours after start of infusion10.0 ± 0.0—
Cycle 2, day 1, 6 hours after start of infusion12.6 ± 11.710.0 ± 0.0
Cycle 3, day 1, 6 hours after start of infusion10.0 ± 0.010.0 ± 0.0
Cycle 4, day 1, 6 hours after start of infusion10.0 ± 0.010.0 ± NA
Cycle 5, day 1, 6 hours after start of infusion10.0 ± 0.010.0 ± NA
SecondaryPhase 1b and Phase 2: Interleukin-6 Concentration

The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) was 125 pg/mL and the limit of detection (LOD) was 20 pg/mL. For calculations of mean cytokine concentrations at every time point across all participants, samples with concentrations below LLOQ were included in the calculation as ½ LLOQ (= 62.5 pg/mL); samples with values below LOD were included as ½ LOD (= 10 pg/mL).

Time frame:
Adults: cycle 1, day 1: 2, 6, 10, 24 hrs after infusion start; day 8: 2, 6, 10 hrs after dose step. Cycles 2-5, day 1: 6 hrs after infusion start. Pediatric: cycle 1, day 1: 6, 10, 24 hrs after infusion start; Cycles 2-5, day 1: 6 hrs after infusion start
Reported as:
Mean · pg/mL
Phase 1b and Phase 2: Interleukin-6 Concentration
pg/mLPhase 1b and Phase 2: Blinatumomab 9/28 μg/Day (Adults)Phase 1b and Phase 2: Blinatumomab 5/15 µg/m²/Day (Pediatric)
Cycle 1, day 1, 2 hours after start of infusion29.1 ± 40.1—
Cycle 1, day 1, 6 hours after start of infusion173 ± 198.1275 ± 371
Cycle 1, day 1, 10 hours after start of infusion186 ± 301.5317 ± 358
Cycle 1, day 1, 24 hours after start of infusion246 ± 907.63714 ± 10740
Cycle 1, day 8, 2 hours after start of infusion14.2 ± 14.5—
Cycle 1, day 8, 6 hours after start of infusion10.0 ± 0.0—
Cycle 1, day 8, 10 hours after start of infusion10.0 ± 0.0—
Cycle 2, day 1, 6 hours after start of infusion20.3 ± 35.617.5 ± 19.8
Cycle 3, day 1, 6 hours after start of infusion16.6 ± 18.636.3 ± 37.1
Cycle 4, day 1, 6 hours after start of infusion10.0 ± 0.062.5 ± NA
Cycle 5, day 1, 6 hours after start of infusion10.0 ± 0.062.5 ± NA
SecondaryPhase 1b and Phase 2: Interleukin-10 Concentration

The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) was 125 pg/mL and the limit of detection (LOD) was 20 pg/mL. For calculations of mean cytokine concentrations at every time point across all participants, samples with concentrations below LLOQ were included in the calculation as ½ LLOQ (= 62.5 pg/mL); samples with values below LOD were included as ½ LOD (= 10 pg/mL).

Time frame:
Adults: cycle 1, day 1: 2, 6, 10, 24 hrs after infusion start; day 8: 2, 6, 10 hrs after dose step. Cycles 2-5, day 1: 6 hrs after infusion start. Pediatric: cycle 1, day 1: 6, 10, 24 hrs after infusion start; Cycles 2-5, day 1: 6 hrs after infusion start
Reported as:
Mean · pg/mL
Phase 1b and Phase 2: Interleukin-10 Concentration
pg/mLPhase 1b and Phase 2: Blinatumomab 9/28 μg/Day (Adults)Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric)
Cycle 1, day 1, 2 hours after start of infusion101 ± 81.1—
Cycle 1, day 1, 6 hours after start of infusion597 ± 637153 ± 94.7
Cycle 1, day 1, 10 hours after start of infusion423 ± 373230 ± 178
Cycle 1, day 1, 24 hours after start of infusion400 ± 699641 ± 1168
Cycle 1, day 8, 2 hours after start of infusion28.9 ± 25.7—
Cycle 1, day 8, 6 hours after start of infusion33.1 ± 26.6—
Cycle 1, day 8, 10 hours after start of infusion33.1 ± 26.6—
Cycle 2, day 1, 6 hours after start of infusion220 ± 357142 ± 173
Cycle 3, day 1, 6 hours after start of infusion121 ± 14662.5 ± 0.0
Cycle 4, day 1, 6 hours after start of infusion88.2 ± 93.762.5 ± NA
Cycle 5, day 1, 6 hours after start of infusion36.3 ± 37.162.5 ± NA
SecondaryPhase 1b and Phase 2: Tumor Necrosis Factor-Alpha (TNFα) Concentration

The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) was 125 pg/mL and the limit of detection (LOD) was 20 pg/mL. For calculations of mean cytokine concentrations at every time point across all participants, samples with concentrations below LLOQ were included in the calculation as ½ LLOQ (= 62.5 pg/mL); samples with values below LOD were included as ½ LOD (= 10 pg/mL).

Time frame:
Adults: cycle 1, day 1: 2, 6, 10, 24 hrs after infusion start; day 8: 2, 6, 10 hrs after dose step. Cycles 2-5, day 1: 6 hrs after infusion start. Pediatric: cycle 1, day 1: 6, 10, 24 hrs after infusion start; Cycles 2-5, day 1: 6 hrs after infusion start
Reported as:
Mean · pg/mL
Phase 1b and Phase 2: Tumor Necrosis Factor-Alpha (TNFα) Concentration
pg/mLPhase 1b and Phase 2: Blinatumomab 9/28 μg/Day (Adults)Phase 1b and Phase 2: Blinatumomab 5/15 µg/m²/Day (Pediatric)
Cycle 1, day 1, 2 hours after start of infusion37.3 ± 61.8—
Cycle 1, day 1, 6 hours after start of infusion24.1 ± 23.715.8 ± 17.5
Cycle 1, day 1, 10 hours after start of infusion20.1 ± 21.115.8 ± 17.5
Cycle 1, day 1, 24 hours after start of infusion10.0 ± 0.015.8 ± 17.5
Cycle 1, day 8, 2 hours after start of infusion16.6 ± 32.8—
Cycle 1, day 8, 6 hours after start of infusion10.0 ± 0.0—
Cycle 1, day 8, 10 hours after start of infusion10.0 ± 0.0—
Cycle 2, day 1, 6 hours after start of infusion12.6 ± 11.717.5 ± 19.8
Cycle 3, day 1, 6 hours after start of infusion16.6 ± 18.610.0 ± 0.0
Cycle 4, day 1, 6 hours after start of infusion10.0 ± 0.010.0 ± NA
Cycle 5, day 1, 6 hours after start of infusion10.0 ± 0.010.0 ± NA
SecondaryPhase 1b and Phase 2: Interferon Gamma (IFN-γ) Concentration

The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) was 125 pg/mL and the limit of detection (LOD) was 20 pg/mL. For calculations of mean cytokine concentrations at every time point across all participants, samples with concentrations below LLOQ were included in the calculation as ½ LLOQ (= 62.5 pg/mL); samples with values below LOD were included as ½ LOD (= 10 pg/mL).

Time frame:
Adults: cycle 1, day 1: 2, 6, 10, 24 hrs after infusion start; day 8: 2, 6, 10 hrs after dose step. Cycles 2-5, day 1: 6 hrs after infusion start. Pediatric: cycle 1, day 1: 6, 10, 24 hrs after infusion start; Cycles 2-5, day 1: 6 hrs after infusion start
Reported as:
Mean · pg/mL
Phase 1b and Phase 2: Interferon Gamma (IFN-γ) Concentration
pg/mLPhase 1b and Phase 2: Blinatumomab 9/28 μg/Day (Adults)Phase 1b and Phase 2: Blinatumomab 5/15 µg/m²/Day (Pediatric)
Cycle 1, day 1, 2 hours after start of infusion26.2 ± 24.7—
Cycle 1, day 1, 6 hours after start of infusion52.3 ± 56.241.2 ± 42.8
Cycle 1, day 1, 10 hours after start of infusion65.8 ± 71.664.5 ± 107
Cycle 1, day 1, 24 hours after start of infusion42.1 ± 51.8129 ± 176
Cycle 1, day 8, 2 hours after start of infusion16.3 ± 17.4—
Cycle 1, day 8, 6 hours after start of infusion14.2 ± 14.5—
Cycle 1, day 8, 10 hours after start of infusion14.2 ± 14.5—
Cycle 2, day 1, 6 hours after start of infusion17.9 ± 19.240.0 ± 28.1
Cycle 3, day 1, 6 hours after start of infusion35.8 ± 55.010.0 ± 0.0
Cycle 4, day 1, 6 hours after start of infusion10.0 ± 0.010.0 ± NA
Cycle 5, day 1, 6 hours after start of infusion10.0 ± 0.010.0 ± NA
PrimaryExpansion Cohort: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related TEAEs

TEAEs are defined as those that start between the start of the first infusion of blinatumomab and 30 days after the end of the last infusion during the treatment period. The severity of adverse events was assessed by the investigator according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 as follows: Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death. The investigator used medical judgment to determine if there was a causal relationship (ie, related, unrelated) between an adverse event and blinatumomab.

Time frame:
From the start of the first infusion to 30 days after the end of the last infusion; median (min, max) treatment duration was 55.6 (25, 140) and 28.0 (8, 56) days in the adult and pediatric expansion cohorts, respectively.
Reported as:
Number · participants
Expansion Cohort: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related TEAEs
participantsExpansion Cohort: Blinatumomab 9/28 μg/Day (Adults)Expansion Cohort: Blinatumomab 5/15 µg/m²/Day (Pediatric)
All TEAEs1417
TEAEs ≥ Grade 31115
TEAEs ≥ Grade 477
Serious TEAEs (STEAEs)23
TEAEs Leading to Interruption of Blinatumomab22
STEAEs Leading to Interruption of Blinatumomab00
TEAEs Leading to Blinatumomab Discontinuation01
STEAEs Leading to Blinatumomab Discontinuation00
Fatal TEAEs02
All Treatment-Related (TR) TEAEs1414
TR TEAEs ≥ Grade 399
TR TEAEs ≥ Grade 455
TR STEAEs00
TR TEAEs Leading to Blinatumomab Interruption21
TR STEAEs Leading to Blinatumomab Interruption00
TR TEAEs Leading to Blinatumomab Discontinuation01
TR STEAEs Leading to Blinatumomab Discontinuation00
TR Fatal TEAEs00
SecondaryExpansion Cohort Adult: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment

Hematological assessments were performed from bone marrow biopsy samples. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Hematological remissions were defined by the following criteria: * Complete Remission (CR) is defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts: platelets \> 100,000/µl and absolute neutrophil count (ANC) \> 1,000/µl. * Complete Remission With Partial Hematological Recovery (CRh\*) is defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts: platelets \> 50,000/µl and ANC \> 500/µl.

Time frame:
Within the first 2 cycles of treatment, 12 weeks
Reported as:
Number · percentage of participants
Expansion Cohort Adult: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment
percentage of participantsExpansion Cohort: Blinatumomab 9/28 μg/Day (Adults)
Expansion Cohort Adult: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment78.6 (49.2 to 95.3)
SecondaryExpansion Cohort Pediatric: Percentage of Participants With M1 Remission Within 2 Cycles of Treatment

M1 remission for pediatric participants was defined as ≤ 5% blasts (M1 bone marrow) in the bone marrow and no evidence of disease.

Time frame:
Within the first 2 cycles of treatment, 12 weeks
Reported as:
Number · percentage of participants
Expansion Cohort Pediatric: Percentage of Participants With M1 Remission Within 2 Cycles of Treatment
percentage of participantsExpansion Cohort: Blinatumomab 5/15 µg/m²/Day (Pediatric)
Expansion Cohort Pediatric: Percentage of Participants With M1 Remission Within 2 Cycles of Treatment29.4 (10.3 to 56.0)

Adverse events

Collected over The median treatment duration for blinatumomab was 108 days for Adult Phase 1b Cohort, 56 days for Pediatric Phase 1b Cohort, 56 days for Adult Phase 2 Cohort, 55.6 days for Adult Expansion Cohort and 28 days for Pediatric Expansion Cohort. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1b: Blinatumomab 9/28 μg/Day (Adults)5/5 (100%)0/5 (0%)5/5 (100%)
Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric)7/9 (77.8%)1/9 (11.1%)9/9 (100%)
Phase 2: Blinatumomab 9/28 μg/Day (Adults)15/21 (71.4%)7/21 (33.3%)21/21 (100%)
Expansion Cohort: Blinatumomab 9/28 μg/Day (Adults)0/14 (0%)2/14 (14.3%)14/14 (100%)
Expansion Cohort: Blinatumomab 5/15 µg/m²/Day (Pediatric)2/17 (11.8%)3/17 (17.6%)16/17 (94.1%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPhase 1b: Blinatumomab 9/28 μg/Day (Adults)Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric)Phase 2: Blinatumomab 9/28 μg/Day (Adults)Expansion Cohort: Blinatumomab 9/28 μg/Day (Adults)Expansion Cohort: Blinatumomab 5/15 µg/m²/Day (Pediatric)
SepsisInfections and infestations0/50/90/210/142/17
Shock haemorrhagicVascular disorders0/51/90/210/140/17
Neutrophil count decreasedInvestigations0/50/92/210/140/17
BacteraemiaInfections and infestations0/50/91/211/140/17
StomatitisGastrointestinal disorders0/50/90/211/140/17
Disease progressionGeneral disorders0/50/90/210/141/17
Multiple organ dysfunction syndromeGeneral disorders0/50/90/210/141/17
OverdoseInjury, poisoning and procedural complications0/50/90/210/141/17
ColitisGastrointestinal disorders0/50/91/210/140/17
Cytokine release syndromeImmune system disorders0/50/91/210/140/17
Most frequent other events
Showing 10 of 212
Most frequent other events
EventPhase 1b: Blinatumomab 9/28 μg/Day (Adults)Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric)Phase 2: Blinatumomab 9/28 μg/Day (Adults)Expansion Cohort: Blinatumomab 9/28 μg/Day (Adults)Expansion Cohort: Blinatumomab 5/15 µg/m²/Day (Pediatric)
PyrexiaGeneral disorders1/57/915/214/1415/17
Cytokine release syndromeImmune system disorders4/55/98/215/146/17
HeadacheNervous system disorders3/54/96/213/144/17
NauseaGastrointestinal disorders2/52/99/218/142/17
Febrile neutropeniaBlood and lymphatic system disorders2/55/910/217/144/17
NeutropeniaBlood and lymphatic system disorders2/55/95/216/140/17
VomitingGastrointestinal disorders2/55/93/214/146/17
Alanine aminotransferase increasedInvestigations1/55/94/212/146/17
HypoalbuminaemiaMetabolism and nutrition disorders1/55/92/210/144/17
AnaemiaBlood and lymphatic system disorders1/54/97/214/146/17

Baseline characteristics

Age, Customized
Age, Customized(Participants)Phase 1b: Blinatumomab 9/28 μg/Day (Adults)Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric)Phase 2: Blinatumomab 9/28 μg/Day (Adults)Expansion Cohort: Blinatumomab 9/28 μg/Day (Adults)Expansion Cohort: Blinatumomab 5/15 µg/m²/Day (Pediatric)Total
< 2 years000011
2 to 6 years000055
7 to 17 years09001120
18 to 34 years1065012
35 to 54 years10146021
55 to 64 years201104
≥ 65 years100203
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1b: Blinatumomab 9/28 μg/Day (Adults)Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric)Phase 2: Blinatumomab 9/28 μg/Day (Adults)Expansion Cohort: Blinatumomab 9/28 μg/Day (Adults)Expansion Cohort: Blinatumomab 5/15 µg/m²/Day (Pediatric)Total
Female45129838
Male1495928
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase 1b: Blinatumomab 9/28 μg/Day (Adults)Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric)Phase 2: Blinatumomab 9/28 μg/Day (Adults)Expansion Cohort: Blinatumomab 9/28 μg/Day (Adults)Expansion Cohort: Blinatumomab 5/15 µg/m²/Day (Pediatric)Total
Japanese5921141766
08

Study locations

16 sites
  • National Hospital Organization Nagoya Medical Center
    Nagoya-shi, Aichi 460-0001, Japan
  • Nagoya University Hospital
    Nagoya-shi, Aichi 466-8560, Japan
  • Kyushu University Hospital
    Fukuoka-shi, Fukuoka 812-8582, Japan
  • Gunmaken Saiseikai Maebashi Hospital
    Maebashi-shi, Gunma 371-0821, Japan
  • Sapporo Hokuyu Hospital
    Sapporo-shi, Hokkaido 003-0006, Japan
  • Kobe University Hospital
    Kobe-shi, Hyogo 650-0017, Japan
  • Kanagawa Childrens Medical Center
    Yokohama-shi, Kanagawa 232-8555, Japan
  • Nagasaki University Hospital
    Nagasaki-shi, Nagasaki 852-8501, Japan
  • Niigata Cancer Center Hospital
    Niigata-shi, Niigata 951-8566, Japan
  • Okayama University Hospital
    Okayama-shi, Okayama 700-8558, Japan
  • Osaka City General Hospital
    Osaka-shi, Osaka 534-0021, Japan
  • Osaka Metropolitan University Hospital
    Osaka-shi, Osaka 545-8586, Japan
  • Saitama Childrens Medical Center
    Saitama-shi, Saitama 330-8777, Japan
  • Jichi Medical University Hospital
    Shimotsuke-shi, Tochigi 329-0498, Japan
  • National Cancer Center Hospital
    Chuo-ku, Tokyo 104-0045, Japan
  • National Center for Child Health and Development
    Setagaya-ku, Tokyo 157-8535, Japan
09

References and documents

Publications

  • Horibe K, Morris JD, Tuglus CA, Dos Santos C, Kalabus J, Anderson A, Goto H, Ogawa C. A phase 1b study of blinatumomab in Japanese children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Int J Hematol. 2020 Aug;112(2):223-233. doi: 10.1007/s12185-020-02907-9. Epub 2020 Jun 20. PubMed 32564243 ↗
  • Kiyoi H, Morris JD, Oh I, Maeda Y, Minami H, Miyamoto T, Sakura T, Iida H, Tuglus CA, Chen Y, Dos Santos C, Kalabus J, Anderson A, Hata T, Nakashima Y, Kobayashi Y. Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia. Cancer Sci. 2020 Apr;111(4):1314-1323. doi: 10.1111/cas.14322. Epub 2020 Feb 11. PubMed 31971321 ↗
  • Kobayashi Y, Oh I, Miyamoto T, Lee WS, Iida H, Minami H, Maeda Y, Jang JH, Yoon SS, Yeh SP, Tran Q, Morris J, Franklin J, Kiyoi H. Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Asia Pac J Clin Oncol. 2022 Jun;18(3):311-318. doi: 10.1111/ajco.13609. Epub 2021 Jun 29. PubMed 34185953 ↗
  • Goto H, Ogawa C, Iida H, Horibe K, Oh I, Takada S, Maeda Y, Minami H, Nakashima Y, Morris JD, Kormany W, Chen Y, Miyamoto T. Safety and Efficacy of Blinatumomab in Japanese Adult and Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Final Results from an Expansion Cohort. Acta Haematol. 2022;145(6):592-602. doi: 10.1159/000525835. Epub 2022 Jul 5. PubMed 35790143 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Feb 2019, 44 months.

Results were first posted in Jan 2020, 11 months after primary completion.

Of 114 phase 1/2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 56 and three quarters within 119. This study's 44 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2015
First posted
Apr 9, 2015
StartActual
Jun 4, 2015
Primary completionActual
Feb 6, 2019
CompletionActual
Jul 4, 2019
Results first posted
Jan 10, 2020
Last update
Dec 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02412306
Lead sponsor
Amgen
Collaborators
Amgen Astellas Biopharma K.K.
Responsible party
Sponsor
First posted
Apr 9, 2015
Start date
Jun 4, 2015
Primary completion
Feb 6, 2019
Completion
Jul 4, 2019
Results posted
Jan 10, 2020
Last update
Dec 12, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion